Animal models of chronic pain: Advances and challenges for clinical translation

Journal of Neuroscience Research

Volumn 95, Issue 6, 2017, Pages 1242-1256

  Burma, Nicole E ^a   Leduc Pessah, Heather ^a   Fan, Churmy Y ^a   Trang, Tuan ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

animal models; chronic pain; pain

Indexed keywords

ANIMAL MODEL; ARTHRITIS; CHRONIC INFLAMMATORY PAIN; CHRONIC PAIN; DYSFUNCTIONAL PAIN; NEUROPATHIC PAIN; NONHUMAN; PAIN ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PSYCHOGENIC PAIN; REVIEW; VISCERAL PAIN; ANIMAL; DISEASE MODEL; PRECLINICAL STUDY;

ANALGESIC AGENT;

ANALGESICS; ANIMALS; CHRONIC PAIN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL;

EID: 84994218605     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23768     Document Type: Review

References (220)

1. Ahn DK, Lim EJ, Kim BC, Yang GY, Lee MK, Ju JS, Han SR, Bae YC. 2009. Compression of the trigeminal ganglion produces prolonged nociceptive behavior in rats. Eur J Pain 13:568–575.
2. Aicher S, Silverman M, Winkler C, Bebo B. 2004. Animal models of chronic pain. J Pain 5:S4.
3. Alamanos Y, Voulgari PV, Drosos AA. 2006. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 36:182–188.
4. Alshami AM. 2014. Knee osteoarthritis related pain: a narrative review of diagnosis and treatment. Int J Health Sci 8:85–104.
5. Amit Z, Galina ZH. 1986. Stress-induced analgesia: adaptive pain suppression. Physiol Rev 66:1091–1120.
6. Apkarian AV, Baliki MN, Geha PY. 2009. Towards a theory of chronic pain. Prog Neurobiol 87:81–97.
7. Araldi D, Ferrari LF, Levine JD. 2015. Repeated mu-opioid exposure induces a novel form of the hyperalgesic priming model for transition to chronic pain. J Neurosci 35:12502–12517.
8. Araldi D, Ferrari LF, Levine JD. 2016a. Adenosine-A1 receptor agonist induced hyperalgesic priming type II. Pain 157:698–709.
9. Araldi D, Ferrari LF, Levine JD. 2016b. Gi-protein coupled 5-HT1B/D receptor agonist sumatriptan induces type i hyperalgesic priming. Pain 157:1773–1782.
10. Arden N, Nevitt MC. 2006. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 20:3–25.
11. Ashton JC, Milligan ED. 2008. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr Opin Invest Drugs 9:65–75.
12. Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, Coudore F, Bourinet E, Eschalier A. 2009. Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 6:620–629.
13. Backonja M-M, Stacey B. 2004. Neuropathic pain symptoms relative to overall pain rating. J Pain 5:491–497.
14. Bailey KR, Crawley JN. 2009. Anxiety-related behaviors in mice. In: Buccafusco JJ, editor. Methods of behavior analysis in neuroscience. Boca Raton, FL: CRC Press.
15. Baliki MN, Mansour AR, Baria AT, Apkarian AV. 2014. Functional reorganization of the default mode network across chronic pain conditions. PLoS One 9:e106133.
16. Barbour KE, Boudreau R, Danielson ME, Youk AO, Wactawski-Wende J, Greep NC, LaCroix AZ, Jackson RD, Wallace RB, Bauer DC, Allison MA, Cauley JA. 2012. Inflammatory markers and the risk of hip fracture: the Women's Health Initiative. J Bone Miner Res 27:1167–1176.
17. Bennett GJ, Xie YK. 1988. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 3:87–107.
18. Berge O-G. 2011. Predictive validity of behavioural animal models for chronic pain. Br J Pharmacol 16:1195–1206.
19. Berman RF, Verweij BH, Muizelaar JP. 2000. Neurobehavioral protection by the neuronal calcium channel blocker ziconotide in a model of traumatic diffuse brain injury in rats. J Neurosurg 93:821–828.
20. Bester H, Chapman V, Besson JM, Bernard JF. 2000. Physiological properties of the lamina I spinoparabrachial neurons in the rat. J Neurophysiol 83:2239–2259.
21. Bhatia D, Bejarano T, Novo M. 2013. Current interventions in the management of knee osteoarthritis. J Pharm Bioallied Sci 5:30–38.
22. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. 2006. Preliminary assessment of the efficacy, tolerability, and safety of a cannabis-based medicine (sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45:50–52.
23. Bodnar RJ, Romero MT, Kramer E. 1988. Organismic variables and pain inhibition: roles of gender and aging. Brain Res Bull 21:947–953.
24. Bölcskei K, Petho G, Szolcsányi J. 2010. Noxious heat threshold measured with slowly increasing temperatures: novel rat thermal hyperalgesia models. Methods Mol Biol 617:57–66.
25. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. 2008. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136:380–387.
26. Bourinet E, Altier C, Hildebrand ME, Trang T, Salter MW, Zamponi GW. 2014. Calcium-permeable ion channels in pain signaling. Physiol Rev 94:81–140.
27. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, Schrier DJ, Kilgore KS. 2003. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 11:821–830.
28. Bradshaw H, Miller J, Ling Q, Malsnee K, Ruda MA. 2000. Sex differences and phases of the estrous cycle alter the response of spinal cord dynorphin neurons to peripheral inflammation and hyperalgesia. Pain 85:93–99.
29. Brennan TJ. 1999. Postoperative models of nociception. ILAR J 40:129–136.
30. Buckmaster C. 2014. Americans for medical progress. Animal research leads to Nobel prize once again. Available online at http://www.amprogress.org/_Nobel_2014
31. Butler RK, Finn DP. 2009. Stress-induced analgesia. Prog Neurobiol 88:184–202.
32. Buvanendran A, Kroin JS, Kari MR, Tuman KJ. 2008. A new knee surgery model in rats to evaluate functional measures of postoperative pain. Anesth Analg 107:300–308.
33. Caldwell JC, Tracey WD. 2010. Alternatives to mammalian pain models 2: using Drosophila to identify novel genes involved in nociception. Methods Mol Biol 617:19–29.
34. Carlini EA. 2004. The good and the bad effects of (–)trans-delta-9-tetrahydrocannabinol (delta-9-THC) on humans. Toxicon 44:461–467.
35. Carlton SM, Du J, Tan HY, Nesic O, Hargett GL, Bopp AC, Yamani A, Lin Q, Willis WD, Hulsebosch CE. 2009. Peripheral and central sensitization in remote spinal cord regions contribute to central neuropathic pain after spinal cord injury. Pain 147:265–276.
36. Caruso FS, Goldblum R, Group TMS. 2000. Dextromethorphan, an NMDA-receptor antagonist, enhances the analgesic properties of morphine. Inflammopharmacology 8:161–173.
37. Centers for Disease Control and Prevention. 2013. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2010–2012. MMWR Morbid Mortal Wkly Rep 62:869–873.
38. Cervero F. 1995. Visceral pain: mechanisms of peripheral and central sensitization. Ann Med 27:235–239.
39. Chakour MC, Gibson SJ, Bradbeer M, Helme RD. 1996. The effect of age on A delta- and C-fibre thermal pain perception. Pain 64:143–152.
40. Challa SR. 2015. Surgical animal models of neuropathic pain: pros and cons. Int J Neurosci 125:170–174.
41. Chaplan SR, Pogrel JW, Yaksh TL. 1994. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 269:1117–1123.
42. Cobos EJ, Ghasemlou N, Araldi D, Segal D, Duong K, Woolf CJ. 2012. Inflammation-induced decrease in voluntary wheel running in mice: a nonreflexive test for evaluating inflammatory pain and analgesia. Pain 153:876–884.
43. Costa ED, Minero M, Lebelt D, Stucke D, Canali E, Leach MC. 2014. Development of the horse grimace scale (HGS) as a pain assessment tool in horses undergoing routine castration. PLoS One 9:e92281.
44. Costigan M, Belfer I, Griffin RS, Dai F, Barrett LB, Coppola G, Wu T, Kiselycznyk C, Poddar M, Lu Y, Diatchenko L, Smith S, Cobos EJ, Zaykin D, Allchorne A, Gershon E, Livneh J, Shen P-H, Nikolajsen L, Karppinen J, Männikkö M, Kelempisioti A, Goldman D, Maixner W, Geschwind DH, Max MB, Seltzer Z, Woolf CJ. 2010. Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain J Neurol 133:2519–2527.
45. Coull JAM, Boudreau D, Bachand K, Prescott SA, Nault F, Sík A, De Koninck P, De Koninck Y. 2003. Transsynaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 424:938–942.
46. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, Gribble FM, Woods CG. 2006. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444:894–898.
47. Craig KD, Hyde SA, Patrick CJ. 1991. Genuine, suppressed, and faked facial behavior during exacerbation of chronic low back pain. Pain 46:161–171.
48. D'Amour FE, Smith DL. 1941. A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74–79.
49. Davoody L, Quiton RL, Lucas JM, Ji Y, Keller A, Masri R. 2011. Conditioned place preference reveals tonic pain in an animal model of central pain. J Pain 12:868–874.
50. De Vries P, Villalón CM, Saxena PR. 1999. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 375:61–74.
51. Decosterd I, Woolf CJ. 2000. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87:149–158.
52. Descalzi G, Ikegami D, Ushijima T, Nestler EJ, Zachariou V, Narita M. 2015. Epigenetic mechanisms of chronic pain. Trends Neurosci 38:237–246.
53. Diaz A, Dickenson AH. 1997. Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation. Pain 69:93–100.
54. Dimitroulas T, Duarte RV, Behura A, Kitas GD, Raphael JH. 2014. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. Semin Arthritis Rheum 44:145–154.
55. Dinser R. 2008. Animal models for arthritis. Best Pract Res Clin Rheumatol 22:253–267.
56. Dubin AE, Patapoutian A. 2010. Nociceptors: the sensors of the pain pathway. J Clin Invest 120:3760–3772.
57. Edwards JCW, Szczepański L, Szechiński J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. 2004. Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581.
58. Eikermann-Haerter K, Moskowitz MA. 2008. Animal models of migraine headache and aura. Curr Opin Neurol 21:294–300.
59. Fang H, Beier F. 2014. Mouse models of osteoarthritis: modelling risk factors and assessing outcomes. Nat Rev Rheumatol 10:413–421.
60. Ferrari LF, Bogen O, Levine JD. 2014. Second messengers mediating the expression of neuroplasticity in a model of chronic pain in the rat. J Pain 15:312–320.
61. Ferrari LF, Bogen O, Reichling DB, Levine JD. 2015. Accounting for the delay in the transition from acute to chronic pain: axonal and nuclear mechanisms. J Neurosci 35:495–507.
62. Fillingim R, Wallace M, Herbstman D, Ribeiro-Dasilva M, Staud R. 2008. Genetic contributions to pain: a review of findings in humans. Oral Dis 14:673–682.
63. Fleetwood-Walker SM, Quinn JP, Wallace C, Blackburn-Munro G, Kelly BG, Fiskerstrand CE, Nash AA, Dalziel RG. 1999. Behavioural changes in the rat following infection with varicella-zoster virus. J Gen Virol 80:2433–2436.
64. Fox A, Eastwood C, Gentry C, Manning D, Urban L. 1999. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 81:307–316.
65. Frey M von. 1896. Untersuchungen uber die Sinnesfunctionen der menschlichen Haut. Erste Abhandlung: Druckempfindung und Schmerz. Leipzig: S. Hirzel.
66. Freynhagen R, Wirz S, Rolke R. 2011. [Diagnosis of neuropathic pain]. Ther Umsch Rev Thérapeutique 68:495–500.
67. Frye CA, Cuevas CA, Kanarek RB. 1993. Diet and estrous cycle influence pain sensitivity in rats. Pharmacol Biochem Behav 45:255–260.
68. Fuchs PN, McNabb CT. 2012. The place escape/avoidance paradigm: a novel method to assess nociceptive processing. J Integr Neurosci 11:61–72.
69. Gårdmark M, Höglund AU, Hammarlund-Udenaes M. 1998. Aspects on tail-flick, hot-plate, and electrical stimulation tests for morphine antinociception. Pharmacol Toxicol 83:252–258.
70. Global Industry Analysts, Inc. 2011. Available online at http://www.prweb.com/pdfdownload/8052240.pdf
71. Goldberg DS, McGee SJ. 2011. Pain as a global public health priority. BMC Public Health 11:770.
72. Gonzalez-Nunez V, Rodríguez RE. 2009. The zebrafish: a model to study the endogenous mechanisms of pain. ILAR J 50:373–386.
73. Goulding EH, Schenk AK, Juneja P, MacKay AW, Wade JM, Tecott LH. 2008. A robust automated system elucidates mouse home cage behavioral structure. Proc Natl Acad Sci U S A 105:20575–20582.
74. Graven-Nielsen T, Arendt-Nielsen L. 2002. Peripheral and central sensitization in musculoskeletal pain disorders: an experimental approach. Curr Rheumatol Rep 4:313–321.
75. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K. 2003. Monoiodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol 31:619–624.
76. Hains B, Vera-Portocarrero L. 2011. Animal models of central neuropathic pain. In: Ma C, Zhang J-M, editors. Animal models of pain. New York: Humana Press. p 103–115.
77. Harden N, Cohen M. 2003. Unmet needs in the management of neuropathic pain. J Pain Sympt Manag 25:S12–S17.
78. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. 1988. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77–88.
79. Heiskanen T, Härtel B, Dahl M-L, Seppälä T, Kalso E. 2002. Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain 96:261–267.
80. Hill R. 2000. NK1 (substance P) receptor antagonists—why are they not analgesic in humans? Trends Pharmacol Sci 21:244–246.
81. Holden E, Calvo G, Collins M, Bell A, Reid J, Scott EM, Nolan AM. 2014. Evaluation of facial expression in acute pain in cats. J Small Anim Pract 55:615–621.
82. Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, Clohisy DR, Mantyh PW. 2000. Murine models of inflammatory, neuropathic, and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98:585–598.
83. Houghton AK, Kadura S, Westlund KN. 1997. Dorsal column lesions reverse the reduction of homecage activity in rats with pancreatitis. Neuroreport 8:3795–3800.
84. Imamura Y, Kawamoto H, Nakanishi O. 1997. Characterization of heat–hyperalgesia in an experimental trigeminal neuropathy in rats. Exp Brain Res 116:97–103.
85. Jaggi AS, Jain V, Singh N. 2011. Animal models of neuropathic pain. Fundam Clin Pharmacol 25:1–28.
86. Jensen TS, Finnerup NB. 2014. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol 13:924–935.
87. Ji R-R, Xu Z-Z, Gao Y-J. 2014. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 13:533–548.
88. Johansen JP, Fields HL, Manning BH. 2001. The affective component of pain in rodents: direct evidence for a contribution of the anterior cingulate cortex. Proc Natl Acad Sci U S A 98:8077–8082.
89. Jones CA, Voaklander DC, Johnston DW, Suarez-Almazor ME. 2001. The effect of age on pain, function, and quality of life after total hip and knee arthroplasty. Arch Intern Med 161:454–460.
90. Joseph EK, Chen X, Khasar SG, Levine JD. 2004. Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain 107:147–158.
91. Joseph EK, Reichling DB, Levine JD. 2010. Shared mechanisms for opioid tolerance and a transition to chronic pain. J Neurosci 30:4660–4666.
92. Kamerman P, Koller A, Loram L. 2007. Postoperative administration of the analgesic tramadol, but not the selective cyclooxygenase-2 inhibitor parecoxib, abolishes postoperative hyperalgesia in a new model of postoperative pain in rats. Pharmacology 80:244–248.
93. Kandasamy R, Price TJ. 2015. The pharmacology of nociceptor priming. Hndbk Exp Pharmacol 227:15–37.
94. Karbarz MJ, Luo L, Chang L, Tham C-S, Palmer JA, Wilson SJ, Wennerholm ML, Brown SM, Scott BP, Apodaca RL, Keith JM, Wu J, Breitenbucher JG, Chaplan SR, Webb M. 2009. Biochemical and biological properties of 4-(3-phenyl-[1,2,4]thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. Anesth Analg 108:316–329.
95. Keating SCJ, Thomas AA, Flecknell PA, Leach MC. 2012. Evaluation of EMLA cream for preventing pain during tattooing of rabbits: changes in physiological, behavioural, and facial expression responses. PLoS One 7:e44437.
96. Kehl LJ, Trempe TM, Hargreaves KM. 2000. A new animal model for assessing mechanisms and management of muscle hyperalgesia. Pain 85:333–343.
97. Kehlet H, Jensen TS, Woolf CJ. 2006. Persistent postsurgical pain: risk factors and prevention. Lancet 367:1618–1625.
98. Keller AF, Beggs S, Salter MW, De Koninck Y. 2007. Transformation of the output of spinal lamina I neurons after nerve injury and microglia stimulation underlying neuropathic pain. Mol Pain 3:27.
99. Keogh E, Cochrane M. 2002. Anxiety sensitivity, cognitive biases, and the experience of pain. J Pain 3:320–329.
100. Kim H, Sung B, Mao J. 2010. Animal models of acute surgical pain. Methods Mol Biol 617:31–39.
101. Kim J-S, Kroin JS, Buvanendran A, Li X, van Wijnen AJ, Tuman KJ, Im H-J. 2011. Characterization of a new animal model for evaluation and treatment of back pain due to lumbar facet joint osteoarthritis. Arthritis Rheum 63:2966–2973.
102. Kim J-S, Ahmadinia K, Li X, Hamilton JL, Andrews S, Haralampus CA, Xiao G, Sohn H-M, You J-W, Seo Y-S, Stein GS, Van Wijnen AJ, Kim S-G, Im H-J. 2015. Development of an experimental animal model for lower back pain by percutaneous injury-induced lumbar facet joint osteoarthritis. J Cell Physiol 230:2837–2847.
103. Kim J-YV, Megat S, Moy JK, Asiedu MN, Mejia GL, Vagner J, Price TJ. 2016. Neuroligin-2 regulates spinal GABAergic plasticity in hyperalgesic priming, a model of the transition from acute to chronic pain. Pain 157:1314–1324.
104. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH. 2009. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330:902–910.
105. Kontinen VK, Meert TF. 2002. Vocalization responses after spinal administration of bicuculline or strychnine in rats. Neuromodulation 5:221–230.
106. Kvall SA, Lofland KR, Nigro C. 1999. Clinical correlates of pain variability in chronic pain. J Back Musculoskel Rehabil 13:87–92.
107. Lacroix-Fralish ML, Mogil JS. 2009. Progress in genetic studies of pain and analgesia. Annu Rev Pharmacol Toxicol 49:97–121.
108. Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, Glick S, Ingrao J, Klassen-Ross T, LaCroix-Fralish ML, Matsumiya L, Sorge RE, Sotocinal SG, Tabaka JM, Wong D, van den Maagdenberg AMJM, Ferrari MD, Craig KD, Mogil JS. 2010. Coding of facial expressions of pain in the laboratory mouse. Nat Methods 7:447–449.
109. Lavich TR, Cordeiro RSB, Silva PMR, Martins MA. 2005. A novel hot-plate test sensitive to hyperalgesic stimuli and nonopioid analgesics. Braz J Med Biol Res 38:445–451.
110. Le Bars D, Gozariu M, Cadden SW. 2001. Animal models of nociception. Pharmacol Rev 53:597–652.
111. Leach MC, Klaus K, Miller AL, Perrotolo MS di, Sotocinal SG, Flecknell PA. 2012. The assessment of postvasectomy pain in mice using behaviour and the mouse grimace scale. PLoS One 7:e35656.
112. Lee BH, Won R, Baik EJ, Lee SH, Moon CH. 2000. An animal model of neuropathic pain employing injury to the sciatic nerve branches. Neuroreport 11:657–661.
113. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, Volpe JJ, Vartanian T. 2003. Activation of innate immunity in the CNS triggers neurodegeneration through a toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 100:8514–8519.
114. Lester LS, Fanselow MS. 1985. Exposure to a cat produces opioid analgesia in rats. Behav Neurosci 99:756–759.
115. Lynch JL, Gallus NJ, Ericson ME, Beitz AJ. 2008. Analysis of nociception, sex, and peripheral nerve innervation in the TMEV animal model of multiple sclerosis. Pain 136:293–304.
116. Mangoni AA, Jackson SHD. 2004. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14.
117. Mapplebeck JCS, Beggs S, Salter MW. 2016. Sex differences in pain: a tale of two immune cells. Pain 157:S2–S6.
118. Marker CL, Pomonis JD. 2012. The monosodium iodoacetate model of osteoarthritis pain in the rat. Methods Mol Biol 851:239–248.
119. Martin LL, Setescak LL, Spaulding TC, Helsley GC. 1984. Dibenz[b,e]oxepinalkanoic acids as nonsteroidal anti-inflammatory agents. 4. Synthesis and evaluation of 4-(4,10-dihydro-10-oxothieno[3,2-c] [1]benzoxepin-8-yl)butanol and -butyric acid and related derivatives. J Med Chem 27:372–376.
120. Martin WJ, Loo CM, Basbaum AI. 1999a. Spinal cannabinoids are antiallodynic in rats with persistent inflammation. Pain 82:199–205.
121. Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM. 1999b. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 822:237–242.
122. Martínez-Gómez M, Cruz Y, Salas M, Hudson R, Pacheco P. 1994. Assessing pain threshold in the rat: changes with estrus and time of day. Physiol Behav 55:651–657.
123. Masaki E, Mizuta K, Ohtani N, Kido K. 2016. Early postoperative nociceptive threshold and production of brain-derived neurotrophic factor induced by plantar incision are not influenced with minocycline in a rat: role of spinal microglia. Neurosignals 24:15–24.
124. Matsumiya LC, Sorge RE, Sotocinal SG, Tabaka JM, Wieskopf JS, Zaloum A, King OD, Mogil JS. 2012. Using the mouse grimace scale to re-evaluate the efficacy of postoperative analgesics in laboratory mice. J Am Assoc Lab Anim Sci 51:42–49.
125. McGivern JG. 2007. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat 3:69–85.
126. McLachlan AJ, Bath S, Naganathan V, Hilmer SN, Le Couteur DG, Gibson SJ, Blyth FM 2011. Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. Br J Clin Pharmacol 71:351–364.
127. Mekada K, Abe K, Murakami A, Nakamura S, Nakata H, Moriwaki K, Obata Y, Yoshiki A. 2009. Genetic differences among C57BL/6 substrains. Exp Anim 58:141–149.
128. Meyer-Rosberg K, Burckhardt CS, Huizar K, Kvarnström A, Nordfors LO, Kristofferson A. 2001. A comparison of the SF-36 and Nottingham health profile in patients with chronic neuropathic pain. Eur J Pain 5:391–403.
129. Milinkeviciute G, Gentile C, Neely GG. 2012. Drosophila as a tool for studying the conserved genetics of pain. Clin Genet 82:359–366.
130. Mills CD, Hains BC, Johnson KM, Hulsebosch CE. 2001. Strain and model differences in behavioral outcomes after spinal cord injury in rat. J Neurotrauma 18:743–756.
131. Mogil JS. 2009. Animal models of pain: progress and challenges. Nat Rev Neurosci 10:283–294.
132. Mogil JS. 2012. Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. Nat Rev Neurosci 13:859–866.
133. Mogil JS, Wilson SG, Bon K, Eun Lee S, Chung K, Raber P, Pieper JO, Hain HS, Belknap JK, Hubert L, Elmer GI, Mo Chung J, Devor M. 1999. Heritability of nociception. I. Responses of 11 inbred mouse strains on 12 measures of nociception. Pain 80:67–82.
134. Mogil JS, Chesler EJ, Wilson SG, Juraska JM, Sternberg WF. 2000. Sex differences in thermal nociception and morphine antinociception in rodents depend on genotype. Neurosci Biobehav Rev 24:375–389.
135. Mogil JS, Davis KD, Derbyshire SW. 2010. The necessity of animal models in pain research. Pain 151:12–17.
136. Monach P, Hattori K, Huang H, Hyatt E, Morse J, Nguyen L, Ortiz-Lopez A, Wu H-J, Mathis D, Benoist C. 2007. The K/BxN mouse model of inflammatory arthritis. In: Cope A, editor. Arthritis research. New York: Humana Press. p 269–282.
137. Muley MM, Krustev E, McDougall JJ. 2016. Preclinical assessment of inflammatory pain. CNS Neurosci Ther 22:88–101.
138. Murphy L, Schwartz TA, Helmick CG, Renner JB, Tudor G, Koch G, Dragomir A, Kalsbeek WD, Luta G, Jordan JM. 2008. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum 59:1207–1213.
139. Murray CW, Porreca F, Cowan A. 1988. Methodological refinements to the mouse paw formalin test: an animal model of tonic pain. J Pharmacol Methods 20:175–186.
140. Myers LK, Rosloniec EF, Cremer MA, Kang AH. 1997. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 61:1861–1878.
141. Nagasako EM, Oaklander AL, Dworkin RH. 2003. Congenital insensitivity to pain: an update. Pain 101:213–219.
142. Nemmani KVS, Grisel JE, Stowe JR, Smith-Carliss R, Mogil JS. 2004. Modulation of morphine analgesia by site-specific N-methyl-D-aspartate receptor antagonists: dependence on sex, site of antagonism, morphine dose, and time. Pain 109:274–283.
143. Ness TJ. 1999. Models of visceral nociception. ILAR J 40:119–128.
144. Ness TJ, Gebhart GF. 1988. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat. Brain Res 450:153–169.
145. Nissenbaum J, Devor M, Seltzer Z, Gebauer M, Michaelis M, Tal M, Dorfman R, Abitbul-Yarkoni M, Lu Y, Elahipanah T, delCanho S, Minert A, Fried K, Persson A-K, Shpigler H, Shabo E, Yakir B, Pisanté A, Darvasi A. 2010. Susceptibility to chronic pain following nerve injury is genetically affected by CACNG2. Genome Res 20:1180–1190.
146. Obrosova IG. 2009. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics 6:638–647.
147. Oertel B, Lötsch J. 2008. Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics 9:179–194.
148. Palmer JA, Higuera ES, Chang L, Chaplan SR. 2008. Fatty acid amide hydrolase inhibition enhances the antiallodynic actions of endocannabinoids in a model of acute pain adapted for the mouse. Neuroscience 154:1554–1561.
149. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, Shohami E. 2006. The endocannabinoid 2-AG protects the blood–brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 22:257–264.
150. Panksepp JB, Lahvis GP. 2011. Rodent empathy and affective neuroscience. Neurosci Biobehav Rev 35:1864–1875.
151. Parent AJ, Beaudet N, Beaudry H, Bergeron J, Bérubé P, Drolet G, Sarret P, Gendron L. 2012. Increased anxiety-like behaviors in rats experiencing chronic inflammatory pain. Behav Brain Res 229.
152. Percie du Sert N, Rice ASC. 2014. Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain. Br J Pharmacol 171:2951–2963.
153. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V. 2007. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52:415–422.
154. Pfau DB, Klein T, Putzer D, Pogatzki-Zahn EM, Treede R-D, Magerl W. 2011. Analysis of hyperalgesia time courses in humans after painful electrical high-frequency stimulation identifies a possible transition from early to late LTP-like pain plasticity. Pain 152:1532–1539.
155. Phillips K, Clauw DJ. 2011. Central pain mechanisms in chronic pain states—maybe it is all in their head. Best Pract Res Clin Rheumatol 25:141–154.
156. Pickering G, Jourdan D, Eschalier A, Dubray C. 2001. [Impact of age on pain perception and analgesic pharmacology]. Presse Méd 30:754–758.
157. Priest BT, Kaczorowski GJ. 2007. Blocking sodium channels to treat neuropathic pain. Expert Opin Ther Targets 11:291–306.
158. Protheroe SM. 1991. Congenital insensitivity to pain. J R Soc Med 84:558–559.
159. Randall LO, Selitto JJ. 1957. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 111:409–419.
160. Reichling DB, Levine JD. 2009. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci 32:611–618.
161. Reitz M-C, Hrncic D, Treede R-D, Caspani O. 2016. A comparative behavioural study of mechanical hypersensitivity in two pain models in rats and humans. Pain 157:1248–1258.
162. Richardson CA. 2015. The power of automated behavioural homecage technologies in characterizing disease progression in laboratory mice: a review. Appl Anim Behav Sci 163:19–27.
163. Roddy E, Zhang W, Doherty M. 2007. The changing epidemiology of gout. Nat Clin Pract Rheumatol 3:443–449.
164. Ruan MZC, Patel RM, Dawson BC, Jiang M-M, Lee BHL. 2013. Pain, motor, and gait assessment of murine osteoarthritis in a cruciate ligament transection model. Osteoarthritis Cartilage 21:1355–1364.
165. Schmader KE. 2002. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 18:350–354.
166. Schött E, Berge OG, Angeby-Möller K, Hammarström G, Dalsgaard CJ, Brodin E. 1994. Weight bearing as an objective measure of arthritic pain in the rat. J Pharmacol Toxicol Methods 31:79–83.
167. Scott DA, Wright CE, Angus JA. 2002. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol 451:279–286.
168. Seltzer Z, Dubner R, Shir Y. 1990. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43:205–218.
169. Shir Y, Zeltser R, Vatine J-J, Carmi G, Belfer I, Zangen A, Overstreet D, Raber P, Seltzer Z. 2001. Correlation of intact sensibility and neuropathic pain-related behaviors in eight inbred and outbred rat strains and selection lines. Pain 90:75–82.
170. Sluka KA. 1998. Blockade of N- and P/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation. J Pharmacol Exp Ther 287:232–237.
171. Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ. 2002. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 96:119–127.
172. Sorge RE, LaCroix-Fralish ML, Tuttle AH, Sotocinal SG, Austin J-S, Ritchie J, Chanda ML, Graham AC, Topham L, Beggs S, Salter MW, Mogil JS. 2011. Spinal cord toll-like receptor 4 mediates inflammatory and neuropathic hypersensitivity in male but not female mice. J Neurosci 31:15450–15454.
173. Sorge RE, Trang T, Dorfman R, Smith SB, Beggs S, Ritchie J, Austin J-S, Zaykin DV, Meulen HV, Costigan M, Herbert TA, Yarkoni-Abitbul M, Tichauer D, Livneh J, Gershon E, Zheng M, Tan K, John SL, Slade GD, Jordan J, Woolf CJ, Peltz G, Maixner W, Diatchenko L, Seltzer Z, Salter MW, Mogil JS. 2012. Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med 18:595–599.
174. Sorge RE, Mapplebeck JCS, Rosen S, Beggs S, Taves S, Alexander JK, Martin LJ, Austin J-S, Sotocinal SG, Chen D, Yang M, Shi XQ, Huang H, Pillon NJ, Bilan PJ, Tu Y, Klip A, Ji R-R, Zhang J, Salter MW, Mogil JS. 2015. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci 18:1081–1083.
175. Spofford CM, Mohan S, Kang S, Jang JH, Brennan TJ. 2011. Evaluation of leukemia inhibitory factor (LIF) in a rat model of postoperative pain. J Pain 12:819–832.
176. Stein C, Millan MJ, Herz A. 1988. Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. Pharmacol Biochem Behav 31:445–451.
177. Stucky CL, Gold MS, Zhang X. 2001. Mechanisms of pain. Proc Natl Acad Sci U S A 98:11845–11846.
178. Sufka KJ. 1994. Conditioned place preference paradigm: a novel approach for analgesic drug assessment against chronic pain. Pain 58:355–366.
179. Sun WH, Chen CC. 2016. Roles of proton-sensing receptors in the transition from acute to chronic pain. J Dent Res 95:135–142.
180. Takasaki I, Andoh T, Shiraki K, Kuraishi Y. 2000. Allodynia and hyperalgesia induced by herpes simplex virus type-1 infection in mice. Pain 86:95–101.
181. Tena B, Escobar B, Arguis MJ, Cantero C, Rios J, Gomar C. 2012. Reproducibility of electronic von Frey and von Frey monofilaments testing. Clin J Pain 28:318–323.
182. The National Academies Press. 2011. Institute of medicine report from the committee on advancing pain research, care, and education: relieving pain in America, a blueprint for transforming prevention, care, education, and research. Available online at http://books.nap.edu/openbook.php?record_id=13172&page=1
183. Tillu DV, Hassler SN, Burgos-Vega CC, Quinn TL, Sorge RE, Dussor G, Boitano S, Vagner J, Price TJ. 2015. Protease-activated receptor 2 activation is sufficient to induce the transition to a chronic pain state. Pain 156:859–867.
184. Toia F, Giesen T, Giovanoli P, Calcagni M. 2015. A systematic review of animal models for experimental neuroma. J Plast Reconstr Aesthet Surg 68:1447–1463.
185. Torrance N, Smith BH, Bennett MI, Lee AJ. 2006. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 7:281–289.
186. Trang T, Salter MW. 2012. P2X4 purinoceptor signaling in chronic pain. Purinergic Signal 8:621–628.
187. Trang T, Al-Hasani R, Salvemini D, Salter MW, Gutstein H, Cahill CM. 2015. Pain and poppies: the good, the bad, the ugly of opioid analgesics. J Neurosci 35:13879–13888.
188. Twillman RK. 2007. Mental disorders in chronic pain patients. J Pain Palliat Care Pharmacother 21:13–19.
189. Vadakkan KI, Jia YH, Zhuo M. 2005. A behavioral model of neuropathic pain induced by ligation of the common peroneal nerve in mice. J Pain 6:747–756.
190. van den Berg WB, Joosten LA, Helsen M, van de Loo FA. 1994. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 9:237–243.
191. Vehof J, Zavos HMS, Lachance G, Hammond CJ, Williams FMK. 2014. Shared genetic factors underlie chronic pain syndromes. Pain 155:1562–1568.
192. von Hehn CA, Baron R, Woolf CJ. 2012. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 73:638–652.
193. Wall PD, Devor M, Inbal R, Scadding JW, Schonfeld D, Seltzer Z, Tomkiewicz MM. 1979. Autotomy following peripheral nerve lesions: experimental anaesthesia dolorosa. Pain 7:103–111.
194. Wallace MS, Charapata SG, Fisher R, Byas-Smith M, Staats PS, Mayo M, McGuire D, Ellis D, The Ziconotide Nonmalignant Pain Study 96–002 Group. 2006. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 9:75–86.
195. Wallace VCJ, Blackbeard J, Segerdahl AR, Hasnie F, Pheby T, McMahon SB, Rice ASC. 2007. Characterization of rodent models of HIV-gp120 and antiretroviral-associated neuropathic pain. Brain 130:2688–2702.
196. Wang LX, Wang ZJ. 2003. Animal and cellular models of chronic pain. Adv Drug Deliv Rev 55:949–965.
197. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet J-P. 2010. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 182:E694–E701.
198. Way JC, Chalfie M. 1989. The mec-3 gene of Caenorhabditis elegans requires its own product for maintained expression and is expressed in three neuronal cell types. Genes Dev 3:1823–1833.
199. Weyer AD, Zappia KJ, Garrison SR, O'Hara CL, Dodge AK, Stucky CL. 2016. Nociceptor sensitization depends on age and pain chronicity(1,2,3). eNeuro 3.
200. Wiesenfeld-Hallin Z. 2005. Sex differences in pain perception. Gend Med 2:137–145.
201. Wiffen PJ, Wee B, Moore RA. 2013. Oral morphine for cancer pain. Cochrane Database Syst Rev 7:CD003868.
202. Wijnvoord N, Albuquerque B, Häussler A, Myrczek T, Popp L, Tegeder I. 2010. Interstrain differences of serotonergic inhibitory pain control in inbred mice. Mol Pain 6:70.
203. Williams JA, Day M, Heavner JE. 2008. Ziconotide: an update and review. Expert Opin Pharmacother 9:1575–1583.
204. Williams RO, Feldmann M, Maini RN. 1992. Antitumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89:9784–9788.
205. Woolf CJ. 1983. Evidence for a central component of postinjury pain hypersensitivity. Nature 306:686–688.
206. Woolf CJ. 2011. Central sensitization: implications for the diagnosis and treatment of pain. Pain 152:S2–S15.
207. Woolf CJ, Salter MW. 2000. Neuronal plasticity: increasing the gain in pain. Science 288:1765.
208. Woolfe G, Macdonald AD. 1944. The evaluation of the analgesic action of pethidine hydrochloride (demerol). J Pharmacol Exp Ther 80:300–307.
209. Yalcin I, Barthas F, Barrot M. 2014. Emotional consequences of neuropathic pain: insight from preclinical studies. Neurosci Biobehav Rev 47:154–164.
210. Yamamoto T, Sakashita Y. 1998. Differential effects of intrathecally administered N- and P-type voltage-sensitive calcium channel blockers upon two models of experimental mononeuropathy in the rat. Brain Res 794:329–332.
211. Yang F, Sun W, Luo W-J, Yang Y, Yang F, Wang X-L, Chen J. 2016. SDF1-CXCR4 signaling contributes to the transition from acute to chronic pain state. Mol Neurobiol [E-pub ahead of print].
212. Yang GY, Lee MK, Bae YC, Ahn DK. 2009. Intracisternal administration of COX inhibitors attenuates mechanical allodynia following compression of the trigeminal ganglion in rats. Prog Neuropsychopharmacol Biol Psychiatry 33:589–595.
213. Yezierski RP. 2012. The effects of age on pain sensitivity: preclinical studies. Pain Med 13:S27–S36.
214. Yoon C, Young Wook Y, Heung Sik N, Sun Ho K, Jin Mo C. 1994. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 59:369–376.
215. Young Casey C, Greenberg MA, Nicassio PM, Harpin RE, Hubbard D. 2008. Transition from acute to chronic pain and disability: a model including cognitive, affective, and trauma factors. Pain 134:69–79.
216. Zhang J, Echeverry S, Lim TKY, Lee SH, Shi XQ, Huang H. 2015. Can modulating inflammatory response be a good strategy to treat neuropathic pain? Curr Pharm Des 21:831–839.
217. Zhang R-X, Ren K. 2011. Animal models of inflammatory pain. In: Ma C, Zhang J-M, editors. Animal models of pain. New York: Humana Press. p 23–40.
218. Zhou L, Rowley DL, Mi Q-S, Sefcovic N, Matthes HWD, Kieffer BL, Donovan DM. 2014. Murine interstrain polymorphisms alter gene targeting frequencies at the mu opioid receptor locus in embryonic stem cells. Mamm Genome 12:772–778.
219. Zhu Q, Mao L-N, Liu C-P, Sun Y-H, Jiang B, Zhang W, Li J-X. 2016. Antinociceptive effects of vitexin in a mouse model of postoperative pain. Sci Rep 6:19266.
220. Zogopoulos P, Vasileiou I, Patsouris E, Theocharis SE. 2013. The role of endocannabinoids in pain modulation. Fundam Clin Pharmacol 27:64–80.